Search

Displaying results 1541 - 1550 of 8468 in total
  1. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    This has led to the development of newer synthetic surfactants such as lucinactant (Surfaxin), which contains sinapultide. … Sinapultide (also known as KL4 peptide) is a synthetic protein used to mimic human lung surfactant protein B.[L2502] This protein has a weight of 2469.40.

  2. Drug

    Aliskiren

    go.drugbank.com/drugs/DB09026
    ApprovedInvestigational

    [A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. … [L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]

  3. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as

  4. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108] The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  5. Drug

    Factor XIII (human)

    go.drugbank.com/drugs/DB12909
    ApprovedInvestigational

    Within the body, FXIII circulates as a heterotetramer composed of 2 A-subunits and 2 B-subunits (A2B2)[A32363]. … Also known as Fibrin Stabilizing Factor (FSF), Factor XIII is an endogenously produced coagulation factor and the final enzyme within the blood coagulation cascade.

  6. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    Elbasvir is available as a fixed-dose combination product with [grazoprevir] (tradename: Zepatier) used for the treatment of chronic hepatitis C. … [L852] Treatment options for chronic hepatitis C have advanced significantly since 2011, with the development of direct-acting antivirals (DAAs) such as elbasvir.

  7. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin was granted FDA approval on 15 December 2004.[L17933]

  8. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. … In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates

  9. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    severe complications [L31968] thus the drug was not approved as a treatment for COVID-19. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in

  10. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    [A258393,A258398] Rezafungin is active against _Candida albicans_, _Candida glabrata_, _Candida parapsilosis_ and _Candida tropicalis_, as well as other _Candida_ and _Aspergillus_ spp. … [A258393,L45633] Unlike other echinocandins such as [caspofungin] and [micafungin], rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining